Chronic inflammatory demyelinating polyneuropathy (CIDP) after cilta-cel therapy
M Korenkov1, J Liebaert1, S Yousefian1,2,3,4
1Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität and Humboldt-Universität zu Berlin, Berlin, Germany.
Ciltacabtagene-autoleucel CAR-T therapy can cause chronic inflammatory demyelinating polyneuropathy (CIDP). This severe complication may stem from bystander T-cells, suggesting T-cell-depleting therapy could improve outcomes.
Area of Science:
- Immunology
- Neurology
- Oncology
Background:
- Ciltacabtagene-autoleucel (cilta-cel) is an effective CAR-T therapy for relapsed/refractory multiple myeloma.
- However, cilta-cel can lead to severe immune-mediated toxicities.
More Related Videos
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
09:56A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
Related Concept Videos
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune...
